Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
INmune Bio Inc. (INMB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.20, with a market capitalisation of $64.67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.09 to $2.60. This page covers its latest market performance, valuation, price trends and company information.
$64.67M | |
$2.28 | |
$30.37 | |
$1.09 | |
$2.26 | |
8.00 | |
721.98K | |
-- | |
$2.60 | |
$1.09 | |
-- | |
-- |
INmune Bio Inc. (INMB) is trading at $2.20 in pre-market trading as of 2026-09-16 10:05:00, down 2.83% ($0.06) from the previous close of $2.26
Pre-market trading shows how investors are pricing INMB before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, INmune Bio Inc. (INMB) moved from $2.44 to $2.20, representing a decline of 10.00% ($0.24).
The stock traded between $2.18 and $2.60 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 341.81 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 73.2%
INMB is currently trading at $2.20, placing it 73.2% of the way from its 52-week low of $1.09 to its 52-week high of $2.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of INmune Bio Inc. (INMB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.